COVID VaccinesReturn to WorkMental Health

Martin Shkreli Has a Lot to Say About Mylan’s EpiPen

August 26, 2016, 9:32 PM UTC
Former KaloBios Pharmaceuticals Chief Executive Officer Martin Shkreli Court Appearance
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals LLC, smiles while exiting federal court in the Brooklyn borough of New York, U.S., on Wednesday, Feb. 3, 2016. Shkreli, charged with securities fraud and called before a congressional panel, has replaced his legal team with Benjamin Brafman, the lawyer who helped get Sean "Diddy" Combs acquitted of gun and bribery charges in 2001. Photographer: Peter Foley/Bloomberg via Getty Images
Photograph by Peter Foley — Bloomberg via Getty Images

The problem with Martin Shkreli, the former biopharma executive who was indicted for securities fraud, is you can never tell when he’s being serious or just trolling lawmakers for whom he has shown clear disdain.

On Thursday, Shkreli sent out a series of Tweets to @OversightDems, the Twitter account for the Committee on Oversight and Government Reform, led by ranking member Rep. Elijah Cummings (D-Md.). He responded to a Tweet from that account slamming Mylan’s (MYL) controversial price hike for the severe allergic reaction-fighting EpiPen—a cost increase which Shkreli has said was actually too low. (Mylan has since pledged to boost its patient assistance and discount programs in the wake of tumbling share prices and sharp rebukes from politicians including Hillary Clinton).

Click here to subscribe to our upcoming Brainstorm Health Daily Newsletter.

Shkreli asked the Democrats if there was any chance he could “come through this time and actually testify,” to which the committee replied yes—but only if he was prepared to stop invoking the Fifth Amendment. During his own hearing related to drug prices in February, Shkreli consistently pleaded the Fifth on advice of counsel.

Shkreli seemed to imply he’s open to speaking out and offering his ideas on the matter.

In the (probably unlikely) event that Shkreli is being serious, what might some of his “insight and potential solutions” look like? He may have already dropped us a hint on Wednesday. In the midst of defending Mylan’s price hike and arguing that the firm’s profit margin is far too low for a company that sells a life-saving drug, Shkreli offered the following:


Some Twitter users noted that the suggestion sounds highly unusual coming from a naked capitalism proponent like Shkreli. And in his reply, he once again melded potential seriousness with sarcasm and mockery. “Just generics,” he wrote. “So old medicines aren’t prone to shortages, price increases or other capitalism. We do it for water.”